HDT Bio Revenue and Competitors

Seattle, WA USA

Location

#2070

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • HDT Bio's estimated annual revenue is currently $9.3M per year.(i)
  • HDT Bio's estimated revenue per employee is $155,000

Employee Data

  • HDT Bio has 60 Employees.(i)
  • HDT Bio grew their employee count by 15% last year.

HDT Bio's People

NameTitleEmail/Phone
1
Co-Founder & Senior AdvisorReveal Email/Phone
2
Co-Founder & COOReveal Email/Phone
3
Co-Founder & CEOReveal Email/Phone
4
ControllerReveal Email/Phone
5
Director Clinical OperationsReveal Email/Phone
6
Director, Regulatory AffairsReveal Email/Phone
7
Senior DirectorReveal Email/Phone
8
Director VirologyReveal Email/Phone
9
Director FormulationsReveal Email/Phone
10
Associate Director Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is HDT Bio?

HDT Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies.

keywords:N/A

N/A

Total Funding

60

Number of Employees

$9.3M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HDT Bio News

2022-04-06 - HDT Bio Demonstrates RNA Vaccines Matched to SARS ...

HDT Bio's COVID-19 vaccine is significantly different from current mRNA vaccines. Using self-replicating RNA, which is designed to amplify...

2022-03-30 - HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of ...

HDT Bio's innovative vaccine uses a proprietary lipid nanoparticle carrier system for delivery of RNA. The vaccine is significantly different...

2022-03-22 - Gennovas mRNA vaccine in legal storm after HDT Bio Corp sues Emcure

HDT says that its vaccine candidate 'dramatically' improves upon the existing mRNA vaccines in two ways – first it uses a special form of mRNA...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.4M605%N/A
#2
$14.6M60-6%N/A
#3
$7.8M60N/AN/A
#4
$7.8M60N/AN/A
#5
$12.3M6013%N/A